- Solve real problems with our hands-on interface
- Progress from basic puts and calls to advanced strategies
Interactive Options Course
Posted September 18, 2026 at 9:45 am
The Claude maker has set up a Bay Area lab for real-world experiments and lab automation as it expands life-science work beyond computer-only research.
Anthropic, the company behind the Claude chatbot, has set up a wet lab in the San Francisco Bay Area, moving its life-science work from computer simulations into real-world biology, Reuters reports.
A wet lab is where ideas get tested with actual cells, chemicals, and lab equipment, not just on a computer. Anthropic’s head of life sciences, Eric Kauderer-Abrams, told Reuters that “the final test” for biology work will still be real experiments for a while, which is why the firm wants some work in-house and some handled by outside partners. It’s also exploring lab automation, including using Claude to direct robotic units with limited human intervention, while keeping human oversight for safety. The move extends its life-sciences push, from a Claude Science offering to an August “Model Hardware Standard” meant to help AI systems operate lab equipment, alongside collaborations with drugmakers like Genentech (Roche’s biotech unit), Bristol Myers Squibb, and Novo Nordisk. But it also highlights a hard constraint: even if AI helps find a promising molecule faster, turning that into an approved medicine still requires years of human testing to prove it’s safe and works.
Zooming out: Isomorphic Labs’ end-of-2026 clinic goal sets a realistic timeline.
Anthropic’s wet lab is a meaningful shift from “we can predict it” to “we can verify it,” which could speed up preclinical work, like refining molecules and lab protocols through rapid, repeatable experiments. Still, Anthropic says the facility isn’t for drug discovery specifically and that it’s not running clinical trials for now, so the longest bottleneck remains untouched. Reuters notes Alphabet’s Isomorphic Labs, which has worked for years to reach patients, delayed its goal to get to the clinic to the end of 2026. That’s the better benchmark than software-style release cycles: near-term progress is more likely to show up as faster preclinical iteration and better automation tools, not a quick march to patient-ready drugs.
—
Originally Posted September 18, 2026 – Anthropic Steps Into The Wet Lab To Test AI Biology
Information posted on IBKR Campus that is provided by third-parties does NOT constitute a recommendation that you should contract for the services of that third party. Third-party participants who contribute to IBKR Campus are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.
This material is from Finimize and is being posted with its permission. The views expressed in this material are solely those of the author and/or Finimize and Interactive Brokers is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to buy or sell any security. It should not be construed as research or investment advice or a recommendation to buy, sell or hold any security or commodity. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.
Related Articles
Join The Conversation
For specific platform feedback and suggestions, please submit it directly to our team using these instructions.
If you have an account-specific question or concern, please reach out to Client Services.
We encourage you to look through our FAQs before posting. Your question may already be covered!